论文部分内容阅读
本文通过肝纤维化动物模型、扩大临床应用及与血清HA和PCⅢ水平的平行比较，进一步评价了血清PLD活性测定在慢性肝病诊断中的意义。模型显示，PLD活性变化与肝纤维化平均积分（Mf）呈“剪刀差”改变。6周前PLD活性随Mf增加而升高，6周后Mf继续增加而PLD活性逐渐降至正常，提示PLD主要是反应映肝纤维化进展，并不反映肝纤维化量的多少。慢活肝和代偿期肝硬化患者，PLD升高最明显，显著高于慢迁肝和失代偿期肝硬化患者。PLD活性与HA及PCⅢ水平呈显著正相关。同时从胶原蛋白合成和降解角度研究胶原蛋白代谢，能更准确地反映肝纤维化的进展情况。
This paper further evaluated the significance of serum PLD activity in the diagnosis of chronic liver disease by animal model of liver fibrosis, clinical application and parallel comparison with the levels of serum HA and PCIII. The model shows that changes in PLD activity and changes in mean integral of liver fibrosis (Mf) showed a “scissors” difference. 6 weeks before PLD activity increased with Mf increased, 6 weeks after Mf continued to increase and PLD activity gradually reduced to normal, suggesting that PLD mainly reflect the progress of fibrosis, does not reflect the amount of liver fibrosis. PLD increased most significantly in patients with chronic liver failure and decompensated cirrhosis, which were significantly higher than those in patients with chronic liver failure and decompensated cirrhosis. PLD activity was positively correlated with HA and PCⅢ levels. At the same time from the perspective of collagen synthesis and degradation of collagen metabolism, can more accurately reflect the progress of liver fibrosis.